Back to search results

The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

This study, called The ImPreSS Trial, is looking at how genetic information can help doctors make better decisions about medications during and after surgery. You may be eligible if you are an adult (18 years or older) scheduled for an elective surgery (planned surgery) at the University of Chicago. If you join, a blood sample will be taken before your surgery to check your genes. This information will then be shared with your doctors to help them choose medications that are best for you, based on your unique genetic profile. The study aims to see how often doctors use this genetic information and if it reduces the use of high-risk drugs over a five-year period. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 1900 participants.
What's involved
You will have a blood sample taken during a pre-operative visit. Your genetic results will be shared with your doctors.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes related to medication use over a period of five years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03729180

The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

Recruiting
NAAges 18+InterventionalSupportive care
University of Chicago
~1,900 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:Routine Elective Surgery- In patient or out patient elective surgeryBlood test for genetic testingDrug-genetic Profile

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period.
Measured over 5 years
+1 more outcome measured

Conditions

Surgery

Explore related trials

Surgical Procedure

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Peter O'Donnell · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Cancer Clinical Trials Office
[email protected]
1-855-702-8222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients who have planned elective surgical procedures at the University of Chicago
Must be aged 18 years or older

Exclusion

Patients who have undergone, or are being actively considered for, liver or kidney transplantation
Patients with known active or prior leukemia.
Inability to understand and give informed consent to participate.

What this trial measures

  • The frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period.5 years

    To explore the feasibility and utility of implementing broad preemptive pharmacogenomic testing in the perioperative setting by determining the frequency of Genomic Prescribing System (GPS) use by anesthesiologists and pain medicine physicians and associated providers during the perioperative period.

  • Rate of use of high-risk drugs in perioperative setting5 years

    To determine the rate of use high-risk drugs (red or yellow pharmacogenomic risk) in the group of patients for whom pharmacogenomic results are available compared to their rate of use (without provider knowledge of pharmacogenomic risk designation) in the control arm.